Clinical data will be presented at the following upcoming medical meetings:

-- American Society of Hematology annual meeting in New Orleans, LA,
December 7, 2009 - Phase 1 clinical proof-of-concept data on AP24534.

-- San Antonio Breast Cancer Symposium, San Antonio, TX, December 11, 2009
- Phase 2 clinical data on ridaforolimus in combination with trastuzumab
in patients with Her-2 positive metastatic breast cancer.

Upcoming Investor and Partnering Meetings

ARIAD will make a corporate presentation at the following upcoming investor conferences:

-- Lazard Capital Markets 6th Annual Healthcare Conference, New York, NY,
November 17, 2009.

-- Windhover´s Therapeutic Area Partnerships Conference, Boston, MA,
November 18, 2009


-- Complete enrollment in the Phase 2 clinical trial of oral ridaforolimus
in combination with trastuzumab (Herceptin(R)) in patients with Her-2
positive, resistant and refractory metastatic breast cancer. Preliminary
data from this study were announced earlier this quarter, and updated
findings will be presented at the San Antonio Breast Cancer Symposium in
December.